140 related articles for article (PubMed ID: 32919000)
41. Laboratory assays for the evaluation of recombinant hirudin.
Walenga JM; Hoppensteadt D; Koza M; Wallock M; Pifarre R; Fareed J
Haemostasis; 1991; 21 Suppl 1():49-63. PubMed ID: 1894197
[TBL] [Abstract][Full Text] [Related]
42. The anticoagulant mechanism of action of recombinant hirudin (CGP 39393) in plasma.
Lindhout T; Blezer R; Hemker HC
Thromb Haemost; 1990 Nov; 64(3):464-8. PubMed ID: 2096492
[TBL] [Abstract][Full Text] [Related]
43. Locally activity-released bifunctional fusion protein enhances antithrombosis and alleviates bleeding risk.
Shi B; Yu A; Liu Y; Li J; Jin J; Dong C; Wu C
J Thromb Thrombolysis; 2007 Dec; 24(3):283-92. PubMed ID: 17487572
[TBL] [Abstract][Full Text] [Related]
44. Hirudin as anticoagulant in experimental hemodialysis.
Markwardt F; Nowak G; Bucha E
Haemostasis; 1991; 21 Suppl 1():149-55. PubMed ID: 1894190
[TBL] [Abstract][Full Text] [Related]
45. [Research progress in hirudin fusion protein--review].
Zhang CL; Yu AP; Jin JD; Wu CT
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2007 Feb; 15(1):215-8. PubMed ID: 17490558
[TBL] [Abstract][Full Text] [Related]
46. Pretreatment of rabbits with either hirudin, ancrod, or warfarin significantly reduces the immediate uptake of fibrinogen and platelets by the deendothelialized aorta wall after balloon-catheter injury in vivo.
Hatton MW; Ross B; Southward SM; DeReske M; Richardson M
Arterioscler Thromb Vasc Biol; 1998 May; 18(5):816-24. PubMed ID: 9598842
[TBL] [Abstract][Full Text] [Related]
47. An objective perspective on recombinant hirudin: a new anticoagulant and antithrombotic agent.
Fareed J; Walenga JM; Iyer L; Hoppensteadt D; Pifarre R
Blood Coagul Fibrinolysis; 1991 Feb; 2(1):135-47. PubMed ID: 1772981
[TBL] [Abstract][Full Text] [Related]
48. Hirudin interruption of heparin-resistant arterial thrombus formation in baboons.
Kelly AB; Marzec UM; Krupski W; Bass A; Cadroy Y; Hanson SR; Harker LA
Blood; 1991 Mar; 77(5):1006-12. PubMed ID: 1995089
[TBL] [Abstract][Full Text] [Related]
49. [Construction and expression of a fusion protein made of tissue-type plasminogen activator and hirudin in Pichia pastoris].
Yu AP; Shi BX; Dong CN; Jiang ZH; Wu ZZ
Sheng Wu Gong Cheng Xue Bao; 2005 Jul; 21(4):553-7. PubMed ID: 16176091
[TBL] [Abstract][Full Text] [Related]
50. Surface functionalization of anticoagulation and anti-nonspecific adsorption with recombinant hirudin modification.
Zheng Z; Li X; Dai X; Ge J; Chen Y; Du C
Biomater Adv; 2022 Apr; 135():212741. PubMed ID: 35929214
[TBL] [Abstract][Full Text] [Related]
51. Recombinant hirudin as a periprocedural antithrombotic in coronary angioplasty for unstable angina pectoris.
Hafner G; Rupprecht HJ; Luz M; Terres W; Schindel F; Friesen HJ; Heinrichs H; Jessel A; Meyer J; Prellwitz W
Eur Heart J; 1996 Aug; 17(8):1207-15. PubMed ID: 8869862
[TBL] [Abstract][Full Text] [Related]
52. Anticoagulant potential of synthetic and recombinant inhibitors of factor Xa and thrombin in vitro.
Hauptmann J; Kaiser B
Blood Coagul Fibrinolysis; 1993 Aug; 4(4):577-82. PubMed ID: 8218854
[TBL] [Abstract][Full Text] [Related]
53. Anticoagulant actions of tissue factor pathway inhibitor on tissue-factor-dependent plasma coagulation.
Ofosu FA
Semin Thromb Hemost; 1995; 21(2):240-4. PubMed ID: 7660146
[TBL] [Abstract][Full Text] [Related]
54. Thrombin regulation of platelet interaction with damaged vessel wall and isolated collagen type I at arterial flow conditions in a porcine model: effects of hirudins, heparin, and calcium chelation.
Badimon L; Badimon JJ; Lassila R; Heras M; Chesebro JH; Fuster V
Blood; 1991 Jul; 78(2):423-34. PubMed ID: 2070078
[TBL] [Abstract][Full Text] [Related]
55. Binding of annexin V/placental anticoagulant protein I to platelets. Evidence for phosphatidylserine exposure in the procoagulant response of activated platelets.
Thiagarajan P; Tait JF
J Biol Chem; 1990 Oct; 265(29):17420-3. PubMed ID: 2145274
[TBL] [Abstract][Full Text] [Related]
56. The significance of TFPI in clotting assays--comparison and combination with other anticoagulants.
Nordfang O; Kristensen HI; Valentin S; Ostergaard P; Wadt J
Thromb Haemost; 1993 Sep; 70(3):448-53. PubMed ID: 8259547
[TBL] [Abstract][Full Text] [Related]
57. Coagulation factors bound to procoagulant platelets concentrate in cap structures to promote clotting.
Podoplelova NA; Sveshnikova AN; Kotova YN; Eckly A; Receveur N; Nechipurenko DY; Obydennyi SI; Kireev II; Gachet C; Ataullakhanov FI; Mangin PH; Panteleev MA
Blood; 2016 Sep; 128(13):1745-55. PubMed ID: 27432876
[TBL] [Abstract][Full Text] [Related]
58. Anticoagulant efficacy of PEG-Hirudin in patients on maintenance hemodialysis.
Pöschel KA; Bucha E; Esslinger HU; Ulbricht K; Nörtersheuser P; Stein G; Nowak G
Kidney Int; 2004 Feb; 65(2):666-74. PubMed ID: 14717940
[TBL] [Abstract][Full Text] [Related]
59. Platelet functions in recombinant hirudin-anticoagulated blood.
Glusa E; Markwardt F
Haemostasis; 1990; 20(2):112-8. PubMed ID: 2363746
[TBL] [Abstract][Full Text] [Related]
60. Comparison of recombinant hirudin and heparin as an anticoagulant in a cardiopulmonary bypass model.
Walenga JM; Bakhos M; Messmore HL; Koza M; Wallock M; Orfei E; Fareed J; Pifarre R
Blood Coagul Fibrinolysis; 1991 Feb; 2(1):105-11. PubMed ID: 1772977
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
